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EDITORIAL REVIEW
Thromboxane synthesis and action within the kidney
Thromboxane (Tx) A2 is a labile derivative of arachidonic
acid metabolism that amplifies the platelet response to a variety
of aggregating agents [13. In addition, TxA2 contracts vascular
smooth muscle [2] and glomerular mesangial cells [3] through
receptor-mediated actions, resulting in increased intracellular
calcium [4—6]. TxA2 is formed by the sequential cyclooxygen-
ation and peroxidation of arachidonic acid to the prostaglandin
(PG) endoperoxides, PGG2 and PGH2. The last of these com-
pounds is then transformed to TxA2 by a specific TxA2 syn-
thase.
Platelets represent a major source of TxA2 formed in vivo
under physiological conditions. However, TxA2 synthase is
widely distributed in other cells, particularly in macrophages, in
the lung, peritoneum and kidney [7, 8], which may augment
their contribution to systemic TxA2 biosynthesis in disease
states. The most convincing evidence for the biological impor-
tance of TxA2 and its precursor endoperoxides derives from the
beneficial effects of aspirin in platelet-mediated vascular occlu-
sive disease [9]. Aspirin irreversibly inhibits platelet cyclooxy-
genase activity by acetylating a serine residue of the enzyme
PGG/H synthase [10, 11]. This mechanism is presumed to
underlie its effectiveness in preventing death in unstable angina
[12—14] and in patients who have suffered a myocardial infarc-
tion [15], conditions in which TxA2 biosynthesis is augmented
[16].
More recently, evidence has accumulated to support a role
for these eicosanoids in the pathogenesis of various forms of
renal disease. The purpose of this review will be to consider the
role of TxA2 within the kidney and to consider the potential
therapeutic benefit which might derive from modulating TxA2
synthesis and/or action by pharmacological or dietary interven-
tion.
Mechanism of action of TxA2
Due to the evanescence of TxA2, which has a half-life of 30
seconds at physiological pH [1, 17], the receptor site for this
compound has been characterized using structural analogs of
PGH2 and, more recently, TxA2 itself [18—20]. Indeed, the
chemical structure of TxA2 was at first merely hypothesized
and only confirmed 10 years later when a TxA2 macrolactone
was synthesized and the effects on platelets and vascular
smooth muscle of the biologically generated material were
replicated [17]. Given the limitation of the ligands used to
characterize PGH2/TxA2 receptor sites, it has been thought that
both eicosanoids have a similar affinity for a common receptor
site on platelets [21].
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Recent observations suggest that the situation might be more
complex. Thus, the antagonist ligand, GR 32191 [22], identifies
two sites on human platelets; it dissociates rapidly from one
(GRr) and appears to bind irreversibly (GRjrr) to the other [23].
GRirr sites are coupled to phospholipase C and transduce
diacylglycerol formation, phosphoinositide turnover, an in-
crease of intracellular calcium and activation of protein kinase
C. These events are associated with platelet activation and
secretion. GRr sites, by contrast, mediate PGH2/TxA2-evoked
platelet shape change and a major portion of the ligand-induced
increase in intracellular calcium, presumably from an 1P3-
insensitive source [23]. Discrimination of the shape change and
aggregation responses was also achieved with the reversibly
bound agonist ligand, BOP [24], although this observation in
isolation might have been explained by varied degrees of
receptor occupancy necessary to evoke the aggregation and
shape change responses [25]. However, this seems an unlikely
explanation, given the marked distinction between the plasma
half-life of GR 32191 (6 to 7 hrs) and the time to recovery of the
ligand-evoked aggregation response ex vivo, which corre-
sponds to platelet turnover time (8 to 10 days). Thus, the
pattern of inactivation of PGH2/TxA2 receptors on human
platelets is consistent with the existence of distinct subtypes of
the receptor. It is unknown whether these sites represent two
distinct receptor isoforms or varied degrees of posttranslational
modification of a single receptor or if the two sites discriminated
by GR 32191 differ in their affinities for PGH2 and TxA2 [26].
The sequence of a full length cDNA for a PGH2tTxA2
receptor obtained from human placenta has recently been
reported [27]. Hydrophobicity plotting of the deduced amino
acid sequence suggests that the PGH2/TxA2 receptor consists of
seven transmembrane spanning domains, characteristic of the
G protein-linked receptor superfamily. The identity between
this clone and a partial length eDNA from a human megakary-
ocytic cell line was used to suggest the identity of vascular (that
is, placental) and platelet (that is, megakaryocyte-derived)
PGH2/TxA2 receptors [273. Further information at the molecu-
lar level will be necessary to determine if this hypothesis, which
is contrary to much biochemical evidence and precedent with
most other receptors, is supported.
Studies of the respective hierarchies for structurally distinct
agonist and .itagonist ligands in platelets and vascular smooth
muscle cells suggest that tissue specific heterogeneity is likely
[28—303. However, others who have performed similar experi-
ments, have disputed this interpretation of their data [3 1—33].
Recently, additional evidence that supports the existence of
tissue specific heterogeneity of PGH2/TxA2 receptors has been
provided [34]. Thus, dissociation of GR 32191 from vascular
smooth muscle cells, derived from both rat aorta and human
saphenous vein, identifies only a single site, from which the
ligand dissociates rapidly. In addition, we have noted that
platelet activating factor (PAF) heterologously down regulates
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but not GRr sites on human platelets [35]. Consistent with
the absence from vascular smooth muscle cells of the subtype
that mediates aggregation in platelets, agonist evoked responses
in this tissue are not down regulated by PAF [34]. Radiolabeled
ligands have identified a single class of high-affinity specific
binding sites in glomeruli, but no studies have been reported to
date with GR 32191.
PGH2/TxA2 analogs activate phospholipase C in mesangial
cells in a manner analogous to that observed in platelets. They
cause an immediate increment in calcium derived from intra-
cellular stores followed by a sustained elevation for longer than
10 minutes, which is dependent upon extracellular calcium.
These effects are blocked by a PGH2ITxA2 antagonist. Studying
this action of the PGH2/TxA2 mimetic, U46619 and PG!2
analog, ilprost, on proliferation of cultured human mesangial
cells in the presence or absence of growth factors, Mene et al
found multiple functional interactions between eicosanoids and
growth factors in the control of mesangial cell proliferation [36].
In particular, U46619 stimulates proliferation when used alone
but inhibits proliferation when applied concomitantly with
growth factors.
The biochemical mechanisms which regulate the response to
PGH2/TxA2 have been most clearly defined in platelets. Ho-
mologous desensitization of the aggregation response to PGH2/
TxA2 agonists occurs rapidly, with a half-time of two to three
minutes. This results in uncoupling of the aggregation receptor
from its phospholipase C-linked 0 protein [4], with subsequent
loss of receptors from the cell membrane. The nature of the G
protein involved is unknown, although it is insensitive to
pertussis toxin [37], in contrast to that by which thrombin and
PAF activate phospholipase C [37—40]. Coincident with these
events, the platelet adenylate cyclase is sensitized to stimula-
tion at the post-receptor level (351. This effect is transduced
through the GR1 receptor. PGH2/TxA2 released from activated
platelets stimulates PGI2 generation by adjacent endothelial
cells [411. Cross talk between the phospholipase C and adenyl-
ate cyclase pathways within thromboxane stimulated platelets
would serve to amplify the inhibitory effects of PGI2. Finally,
despite the transduction of these effects via the GR1,,. receptor
and some tenuous evidence that the PGH2/TxA2 receptor is
phosphorylated upon desensitization [42], neither desensitiza-
tion of aggregation, nor sensitization of the cyclase, appear
dependent on protein kinase C [35].
PGH2/TxA2 evoked intracellular calcium responses in human
mesangial cells through activation of phospholipase C also
undergo rapid, homologous desensitization [6]. In this system,
the biochemical mechanisms which underlie this effect and the
possible cross talk with other systems remain to be defined. The
density of PGH2/TxA2 binding sites is reduced in mesangial
cells obtained from rats made diabetic with streptozotocin [43],
a condition associated with enhanced glomerular TxA2 synthe-
sis [44].
Evidence for TxA2 synthesis by resident renal cells
The hypothesis that resident renal cells can metabolize ara-
chidonic acid to prostaglandins and TxA2 was based on the
observation that glomerular capillaries have immunoreactive
cyclooxygenase activity [45]. Soon after this observation, two
independent laboratories have documented that isolated rat
glomeruli convert arachidonic acid into prostaglandins and
TxA2 [46, 47]. Subsequent studies documented that eicosanoid
biosynthesis occurs in glomeruli of other species, including
humans [48—50]. Similar conclusions were derived from studies
on renal epithelial and mesangial cells in culture [51, 52].
PGH2/TxA2 evoked intracellular calcium responses in human
mesangial cells through activation of phospholipase C also
undergo rapid, homologous desensitization [61.
Angiotensin II and arginine-vasopressin stimulate glomerular
TxA2 synthesis via specific receptor(s) linked to phospholipase
C [53]. More recently, endothelin has been found to induce the
synthesis of TxA2 by rat and bovine mesangial cells [54, 55].
Indeed studies with antagonists suggest that PGH2/TxA2 recep-
tors mediate the contractile response to endothelin in guinea pig
tracheal strips and rat aorta [56, 57]. In some [54], but not all
[55] systems, the hormonal stimulation of mesangial cell TxA2
can be blocked by lowering the concentration of extracellular
calcium or by incubating the cells with the calcium antagonists,
verapamil or nifedipine.
Factors other than hormones which regulate renal TxA2
biosynthesis include cell-derived mediators, like platelet acti-
vating factor (PAF) and interleukin 1 (IL-l), complement mem-
brane attack complex, immune complexes and endotoxin. PAF
induces TxA2 synthesis by rat mesangial cells in culture through
a receptor-mediated effect [581. IL-i stimulates TxA2 release
alter continuous, prolonged exposure to rat mesangial cells
[59]. This is suggestive of an effect dependent upon new protein
synthesis, perhaps due to regulation of cyclooxygenase mes-
sage, as has been shown in dermal fibroblasts and endothelial
cells [60, 61]. Oxygen-derived free radicals also activate phos-
pholipase A1, thus enhancing prostaglandin and TxA2 synthesis
in isolated glomeruli through an increase in the availability of
arachidonic acid [621. Cultured mesangial cells exhibit a bipha-
sic response to progressively higher concentrations of hydrogen
peroxide. The decrease in eicosanoid formation at higher con-
centrations is probably due to inactivation of cyclooxygenase
[63]. An increase in TxA2 production occurs in rat glomerular
epithelial cells when the terminal complement components
C5b-9 are added to the culture medium [641. E. coli lipopoly-
sacchande stimulates both PGE2 and TxA2 synthesis by cul-
tured mesangial cells in a dose- and time-dependent manner
[65]. Exposure of mesangial cells to immune complexes [661 or
the binding of an antibody to a cell membrane antigen [67] also
promotes arachidonic release and eicosanoid formation in
mesangial cells.
Another important pathway which may result in renal gener-
ation of TxA1 has been reported by Sraer et a! [68] who
demonstrated that human glomeruli released a diffusible factor
capable of stimulating platelet TxA2 synthesis. The clinical
nature of this factor has not yet been fully identified. GC/MS
analysis suggests that at least part of the stimulatory activity is
attributable to saturated and monoenoic acids. Thus, injury to
glomerular cells may activate platelets by a pathway which is
independent from the formation of collagen and leads to local
formation of TxA2
Modulation of renal function by TxA2 in health and disease
Whole-kidney clearance studies in rats and dogs have shown
a consistent fall in glomerular filtration rate (GFR) and in renal
plasma flow (RPF) in response to systemic infusion of stable
prostaglandin endoperoxide analogues [69—71]. Micropuncture
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Fig. 1. Schematic representation of changes in single nephron glornerular filtration rate and its determinants during infusion of the TxA2 mimetic
U-46619 in euvolemic rats. (a), from reference 76 and (b) from reference 69. Abbreviations are: P, mean glomerular transcapillary hydraulic
pressure gradient; Kf, glomerular capillary ultrafiltration coefficient; Qa, glomerular capillary plasma flow rate; Ra and Re, afferent and efferent
arteriolar resistances; SNGFR, single nephron glomerular filtration rate.
studies performed in rats during intraarterial infusion of the
PGH2/TxA2 analog, U46619, have shown a rise in afferent and
efferent arteriolar resistance with a parallel reduction of glomer-
ular capillary flow and single nephron GFR [69] (Fig. 1).
Moreover, in an isolated perfused rat kidney preparation, the
analog decreased both RPF andGFR. However, the decrease in
GFR was more marked than in RPF, suggesting that the
mimetic may act selectively upon afferent resistance vessels or
may reduce GFR by lowering the ultrafiltration coefficient (Kf)
[72].
More recently, this possibility has been addressed directly by
examining the effect of PGH2/TxA2 analogs on renal microves-
sels. This has been done in a hydronephrotic perfused kidney
model that allows direct visualization of the renal microcircu-
lation [73]. Image analysis of afferent and efferent arteriolar
diameters provided direct evidence that PGH2/TxA2 preferen-
tially constricts the afferent arteriole. Of interest, is the obser-
vation that such a constrictor effect of thromboxane was
abolished by calcium antagonists [72]. No changes in K1 were
detected since the single nephron GFR and glomerular capillary
plasma flow rate (Qa) fell in parallel. However, most rats in this
study were evaluated at filtration pressure equilibrium during
infusion of the PGH2/TxA2 analog, so that it was not possible to
calculate exact values of K1. Thus, small TxA2-mediated
changes in Kf may have gone undetected.
Consistent with this possibility, GFR falls by a greater extent
than RPF in the early phase of nephrotoxic nephritis character-
ized by enhanced glomerular TxA2 synthesis, suggesting a fall
in K1 [74]. Similarly, direct measurements of glomerular hemo-
dynamic changes during infusion of antiglomerular basement
membrane antibody [75] indicated a fall in Kf together with an
increase in intraglomerular capillary pressure. On the other
hand, a direct effect of TxA2 on K1 is consistent with in vitro
data showing that endoperoxide analogs contract rat isolated
glomeruli as well as cultured mesangial cells, thereby presum-
ably reducing the filtration surface area in vivo [6, 76].
Recent data have indicated an interesting strain difference
between young SHR and age matched WKY in the renal
vascular reactivity to locally administered angiotensin I! and
TxA2 [77]. Unlike WKY, SHR display an exaggerated vascular
reactivity to both angiotensin II and TxA2, indicating that the
degree of renal vasoconstriction in response to agonists may
vary across strains of animals in a way that is genetically
determined. Whether this would contribute to the sustained
renal vasoconstriction of animals which are hypertensive re-
main to be established.
Angiotensin II, which induces TxA2 synthesis by mesangial
cells, also induces a concentration dependent increase in PGE2
[52] and PG!2 synthesis [78] that causes mesangial relaxation by
promoting an increase in cyclic AMP. This modulating effect of
PGE2 and PG!2 is lost in the presence of cyclooxygenase
inhibitors, so that the mesangial response is amplified and GFR
decreases. Similarly, whole glomeruli decrease their surface
area when incubated with angiotensin I!, and this effect is
exacerbated by prostaglandin inhibition [76].
In a rat model of glycerol-induced acute renal failure the
glomerular synthesis of PGE2 decreased in the early phase of
the disease while TxA2 synthesis was greater in glycerol treated
than in control rats only upon stimulation with arachidonic acid
and at 24 hours after the glycerol administration [79]. These
findings were consistent with other data showing that an inhib-
itor of TxA2 synthesis partially protected another strain of rats
against glycerol-induced acute renal failure [80]. Of interest, an
angiotensin converting enzyme inhibitor did not confer protec-
tion in the same setting, but rather resulted in a significant
increase in renal TxB2 and 6-keto-PGF1 synthesis. This may
indicate that, at least in this model, TxA2 is an important
mediator of damage.
In a more physiological setting, the administration of cyclo-
oxygenase inhibitors to conscious, sodium-replete animals does
not induce changes in RPF and GFR, indicating that a compen-
satory role of vasodilatory prostaglandins for maintaining renal
function is negligible under these circumstances [81—83]. By
contrast, in anesthetized [84] or sodium-deprived animals [81],
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or those with hemorrhagic hypotension [85]or congestive heart
failure [86] blocking the cyclooxygenase leads to a fall in RPF
and GFR. Thus, the potentially adverse effects of increased
production of mesangial cell contractile agonists, including
PGH2/TxA2, is partially offset by relaxant eicosanoids such as
PGE2 and PG!2. Neither TxA2, nor the other eicosanoids,
appear to play an important role in mesangial function under
physiological circumstances. Thus, it is not surprising that a
thromboxane synthase inhibitor does not alter p-aminohippu-
rate or inulin clearance in healthy humans [87], while a throm-
boxane receptor antagonist is capable of increasing RPF and
GFR in patients with lupus nephritis [88].
Measurement of TxA2 biosynthesis
Because of chemical instability of the bicyclic oxane struc-
ture, TxA2 is rapidly hydrolyzed to the chemically stable and
biologically inactive derivative, TxB2. Thus, in vivo as well as
in vitro measurements of TxA2 biosynthesis have relied upon
detection of TxB2 or its enzymatic metabolites [89]. In healthy
human beings, TxB2 is produced at a very low rate, that is, 0.11
ng/kg min' [90], possibly reflecting the low frequency and/or
intensity of stimuli to its secretion under physiologic circum-
stances. In contrast to the low rate of actual in vivo production,
the capacity of platelets to synthesize TxA2 ex vivo in response
to appropriate stimuli (for example, thrombin) is quite substan-
tial; 1 ml of human whole blood incubated at 37°C for one hour
producing almost as much TxB2 as the whole body during the
same period of time, that is, roughly 300 to 400 ng [90]. TxB2
undergoes two major pathways of metabolism in humans [91],
one involving /3-oxidation resulting in the formation of 2,3-
dinor-TxB2 and the other involving dehydrogenation of the
hemiacetal alcohol group at C- 11, resulting in the formation of
a series of metabolites with a delta-lactone ring structure (such
as 1 l-dehydro-TxB2). These enzymatic changes are thought to
occur primarily in the liver, lungs and kidney. A variety of
techniques have been developed to quantitate the plasma levels
and/or the urinary excretion of these metabolites [92, 93]. These
include radioimmunoassay (RIA), enzyme-immunoassay (EIA)
and negative ion-chemical ionization gas chromatography/mass
spectrometry (NICI-GC/MS).
Largely indirect evidence supports the notion that the urinary
excretion of primary unmetabolized eicosanoids, including
TxB2, reflects intrarenal eicosanoid production under physio-
logical circumstances [89] in contrast to the metabolites which
reflect mainly systemic, extrarenal production [89, 94]. The
evidence concerning urinary TxB2 derives from infusion studies
of exogenous TxB2 in healthy subjects [90], from the investiga-
tion of patients with lupus nephritis [88] and from pharmaco-
logic studies of selective and nonselective cyclooxygenase
inhibitors in health and disease [88, 95—97]. These human
studies have measured the urinary excretion of TxB2, and
2,3-dinor-TxB2 and have demonstrated a dissociation of their
excretory pattern (Table 1) in the setting of renal disease. No
information of a similar nature is available from animal studies,
even though measurements of urinary TxB2 have been used
extensively in rat and murine models of renal disease, as
detailed below. Our recent finding that the rat kidney has the
capacity to metabolize TxB2 to 2,3-dinor-TxB2 and that both
are excreted in the urine, implies that under conditions of
enhanced intrarenal synthesis of TxA2, one should expect
Table 1. Differential pattern of excretion of thromboxane B2 and 2,3-
dinor-thromboxane B2 in health and disease
Urinary excretion
Thromboxane 2,3-Dinor-thromboxane
Variable B2 B2
Thromboxane B2 no change time-dependent increase
infusion at
0.1 ng/kg min1
Aspirin no change dose-dependent decrease
20—160 mg/day
Sulindac no change dose-dependent decrease
200—800 mg/day
Lupus nephritis 2- to 5-fold no change
increase
Based on data from references 89—91 and 95—97.
increased urinary excretion of both TxB2 and 2,3-dinor-TxB,
[98]. Correspondingly, while urinary TxB2 may largely derive
from the kidney under physiological circumstances, augmented
extrarenal TxA2 biosynthesis would be expected to be reflected
by increased excretion of TxB2 as well as by its metabolites.
Thus, urinary TxB2 (and its metabolites) is increased in patients
with platelet activation [99] and following both inhalation and
ingestion of TxB2 [100]. Whether proteinuria alters the dispo-
sition of glomerular TxA2 or its availability for further hydrol-
ysis in urine remains to be determined.
Measurement of ex vivo glomerular TxB2 production in
response to added substrate or other stimuli represents a
capacity-related index, conceptually similar to the measure-
ment of TxB2 production during whole blood clotting [101].
Measurement of TxB2 synthesis in isolated glomeruli has been
used extensively to monitor disease-associated changes in
PGH2/TxA2 metabolism. However, the relationship of en-
hanced glomerular TxB2 production, as detected ex vivo, to the
actual rate of TxA2 biosynthesis in vivo remains to be defined.
Measurement of eicosanoid production in isolated glomeruli
may provide useful information on qualitative differences in
disease-related expression of PG-endoperoxide metabolism,
possibly reflecting changes in the cellular source(s) of TxA2
production or upregulation of Tx-synthase gene expression.
Inhibition of TxA2 synthesis and action
Effects on glomerular permeability to macromolecules
Little information is available thus far as to whether the
course of renal disease may be modified by preventing TxA2
synthesis or action. However, several recent studies in animal
models and limited clinical investigation suggests that indices of
disease severity may be modified by this type of intervention.
Some of the most encouraging information has derived from
studies of drug-induced nephrosis. Thus, treatment with a
selective TxA2 synthase inhibitor was shown to reduce urinary
protein excretion without changes in GFR in rats with adriamy-
cm (ADR) induced nephrosis [102]. Whether this reflected a
direct effect of TxA2 on glomerular permeability to proteins or
was the result of changes in glomerular hemodynamics induced
by exaggerated renal TxA2 synthesis was not established by
that study. That pharmacological inhibition of thromboxanc
synthase ameliorates proteinuria in experimental nephrosis has
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been confirmed [103, 1041 using structurally distinct thrombox-
ane synthase inhibitors in a different model of drug-induced
(aminonucleoside) nephrosis. Thromboxane synthase inhibitors
also reduced [105] membrane attack complex (MAC)-induced
proteinuria in the isolated perfused model of passive Heymann
nephritis. In this model, proteinuria develops acutely, making it
unlikely that compositional changes in the basement membrane
underlie the observation. Rather, MAC-mediated cytotoxicity
of epithelial cells may explain proteinuria. Similar to the results
reported earlier in ADR nephrosis, a thromboxane-synthesis
inhibitor diminished proteinuria in both cases; however, the
effect of thromboxane synthesis inhibition on proteinuria was
only partial. Whether this is due to the fact that these com-
pounds do not fully suppress the synthesis of thromboxane or
that factors other than TxA2 may be involved in mediating the
altered glomerular permeability to proteins is still a matter of
speculation. At least one study in humans has documented that
inhibiting thromboxane synthesis may reduce proteinuria and
induce remission of the nephrotic syndrome when it is resistant
to conventional therapy [106].
A recent study of rats made diabetic with streptozotocin also
showed that a thromboxane synthase inhibitor given for six
months reduced urinary TxB2 excretion by 80% and abolished
the rise in urinary albumin that occurs with time in diabetes
[107]. The thromboxane inhibitor also induced an increase in
the clearance of inulin in diabetic animals as compared with
controls. A similar study has shown that the exacerbation of
proteinuria in streptozotocin rats by a high protein diet is
ameliorated by thromboxane synthase inhibition [1081. No
changes in blood pressure or inulin clearance were detected,
suggesting a mechanism unrelated to the vasoconstrictive prop-
erties of TxA2.
The relationship between enhanced glomerular thromboxane
formation and the development of renal disease has also been
recently explored in normotensive rats of the Milan Strain
(MNS) that spontaneously develop an age-related form of
proteinuria and progressive glomerulosclerosis [109]. When
these animals were given a thromboxane synthase inhibitor,
decreased glomerular TxB7 production and proteinuria were
observed together with substantial preservation of RPF and
GFR [110]. Blood pressure was unaltered by the treatment;
however, the number of sclerotic glomeruli was reduced.
In nephritis induced by anti-GBM antibody, inhibitors of
thromboxane synthase reduced proteinuria and partially pre-
vented deterioration of renal function in both rat [111] and
rabbit models [112]. Similar results were obtained by the use of
a PAF receptor antagonist. Since the PAF receptor antagonist
depressed the increment in thromboxane synthesis in immuno-
logically injured glomeruli, it was suggested that its beneficial
effect is mediated by suppression of excessive intrarenal syn-
thesis of TxA2 [112].
These biochemical and pharmacological findings appear to
establish that exaggerated renal thromboxane synthesis may
impair the selective properties of glomerular capillaries. How-
ever, the mechanism(s) for such an effect are less clear. TxA2
may increase glomerular permeability to proteins by a direct,
albeit still ill-defined, effect on glomerular barrier size-selective
properties. Indirect evidence in support of this hypothesis is the
observation that in ADR nephrotic rats, the increased glomer-
ular production of TxA2 [102] is associated with alteration of
both size and charge-dependent permeability of the glomerular
barrier, as indicated by the enhanced fractional clearance of
both neutral and sulfate dextrans as compared to control
animals [113, 114]. Since micropuncture studies in these ani-
mals have shown no changes in the determinants of single
nephron GFR [115, 116], it is tempting to speculate that TxA2
can directly alter the selective properties of the glomerular
capillary barrier. This possibility is further supported by the
finding that part of the effect of PAF on glomerular membrane
permeability is mediated via the secondary release of TxA2.
Another possibility is that TxA2 functions as an intracellular
messenger for the induction of epithelial cell morphological
changes that are associated with leakage of protein through the
glomerular capillary wall.
Effects on Kf
In nephrotoxic serum nephritis induced by anti-GBM anti-
bodies, glomerular TxB2 synthesis is enhanced coincident with
the reduction in GFR [111]. Blocking thromboxane synthesis by
two different inhibitors induced a partial recovery of GFR,
suggesting an effect of TxA, on factors that regulate glomerular
filtration [ill]. Since GFR decreased more than RPF, it is likely
that the K is impaired by anti-GBM serum. The theoretical
possibility that blocking thromboxane synthesis is beneficial in
anti-GBM, because it prevents a TxA2-mediated decrease in Kf,
is consistent with the potent contractile effect of PGH2/TxA2
mimetics on mesangial cells. This is likely to decrease Kf by
reducing the filtration surface area [117].
Another example that indicates a possible role of TxA2 in
decreasing the glomerular filtration surface area in renal disease
is provided by the acute toxicity of cyclosporin A (CsA).
Animals and humans given CsA show a reduction in GFR
associated with a progressive rise in the renal synthesis of TxA,
[118—121], The administration of a TxA2 synthesis inhibitor
results in a significant decrease in the urinary excretion of TxB,
and an increase in GFR in the rat [119]. Enhanced renal
synthesis of TxA2 in CsA-treated animals correlates with the
reduction in GFR but not RPF. This is consistent with the
possibility that TxA2 reduces the Kf by reducing glomerular
surface area.
Effects on afferent and efferent arterioles
Besides having an effect on K, possibly mediated by a
contractile action on mesangial cells, there is evidence that
excessive renal TxA2 synthesis can influence the tone of
afferent and efferent arterioles in renal disease. In a rat model of
endotoxin-induced acute renal failure, the acute increase in
renal vascular resistance and decrease in RPF, GFR and
filtration fraction were prevented by a thromboxane synthesis
inhibitor which also abolished the excessive renal synthesis of
TxA2 [1221. The simultaneous decrease in RPF and GFR and
the effect of the inhibitor in such a model are more consistent
with a TxA2-mediated effect on afferent and efferent arterioles
than on K.
Increased renal production of TxA2 appears also to mediate
the glomerular vasoconstriction that is associated with persist-
ent ureteral obstruction [123]. Treatment with a thromboxane
synthesis inhibitor reverses the vasoconstriction and improves
renal function in this model [124]. Inflammatory cells generate
excessive amounts of peptidoleukotrienes (LTs) in ex vivo
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perfused hydronephrotic kidneys and both endogenous and
exogenous LTC4 stimulates TxA2 synthesis in the hydrone-
phrotic but not in the contralateral kidney [125]. Renal vaso-
constriction is abolished by pretreatment with either a throm-
boxane synthase inhibitor or a leukotrene receptor antagonist
[125]. Evidence that excessive renal TxA2 synthesis mediates
impaired renal function has also been obtained in autoimmune
lupus mice by showing increased intrarenal production of TxB2
in parallel deterioration of renal function, as well as by dietary
manipulation of this pathway [126, 127]. Moreover, Spurney et
al [1271 have found that TxA2 receptor blockade increases GFR
in MRL-lpr mice.
Impairment of renal function in human lupus nephritis may
also be reversed by thromboxane antagonists. Pierucci et al [88]
reported that a TxA2 receptor antagonist but not low-dose
aspirin induced a similar increase in GFR and RPF in such
patients, consistent with an effect of enhanced TxA2 either on
afferent and efferent arterioles or on mesangial cells. It has also
been documented that the intense vasoconstriction which is
associated with rejection of renal allografts is associated with
increased renal TxA2 synthesis [128]. Treatment with a throm-
boxane synthase inhibitor was associated with a decrease in
urinary TxB2 and an increase in RPF and GFR. Since cyclo-
phosphamide also decreased urinary TxB2, a likely source of
the increment in TxB2 in this model is from infiltrating inflam-
matory cells.
Effects on progression of giomerular damage
In the last ten years, several studies have addressed the
progressive nature of renal disease after renal mass has been
reduced surgically. The most attractive hypothesis is that the
increased glomerular pressure and flow that develops in re-
sponse to the initial loss of functioning nephrons causes gb-
merular injury and that this eventually leads to glomeruloscler-
osis [129, 130]. Rats with reduced renal mass also have
increased urinary excretion of TxB2 and chronic administration
of a thromboxane synthase inhibitor decreases urinary protein
excretion and limits glomerular damage [131]. The thrombox-
ane inhibitor in this model also markedly inhibited 'in vitro'
platelet aggregation, suggesting that intrarenal platelet activa-
tion and glomerular thrombosis may play a role in the progres-
sion of the disease after a critical number of nephrons has been
reduced. However, the TxA2 synthesis inhibitor also lowered
blood pressure, leaving open the possibility of an effect related
to this property of the compound. Indeed, neither low dOse
aspirin nor a thromboxane receptor antagonist—both of which
failed to influence hemodynamics—retarded progressive renal
disease in the remnant kidney model [132, 133].
In another model of progressive renal insufficiency that
shares many biologic similarities with the human condition,
immune complex nephritis induced by ferritin-anti-ferritin com-
plexes in DahI-salt sensitive rats, a thromboxane synthase
inhibitor, ameliorated urinary protein excretion and renal func-
tion [134]. Histological examination of the kidney showed that
animals given the thromboxane synthase inhibitor were also
significantly protected from glomeruloscberosis. These findings
are consistent with those of others [110, 126] in other experi-
mental models of progressive nephropathy (that is, Milan
normotensive rats and NZBINZW F1 mice) in which a protec-
tive effect of thromboxane synthase inhibitors on renal injury
was evident.
Manipulating the thromboxane biosynthetic pathway in renal
disease may also be beneficial because it limits platelet activa-
tion, one of the possible mechanisms involved in the progres-
sion of renal disease. This possibility is consistent with an
observational study that suggested that antiplatelet agents
slowed the deterioration of renal function and prevented the
development of end-stage renal disease in patients with mem-
branoproliferative glomerulonephritis [135]. Intraglomerular
platelet aggregation could facilitate mesangial cell proliferation
and excessive generation of mesangial matrix. Thus, platelet-
derived growth factor (PDGF) binds to specific receptors on
cultured mesangial cells and stimulates DNA synthesis and
cellular proliferation [136]. In vitro studies have documented
that another platelet product, transforming growth factor-$
(TGF-j3) stimulates synthesis of the extracellular matrix com-
ponents, collagen IV and laminin and the proteoglycans, bigly-
can and ecorin, by cultured mesangial cells [137, 1381 without
stimulation of cell proliferation. TGF-3 mediates proteoglycan
production and mesangial matrix expansion in vivo in a rat
model of glomerulonephritis induced by anti-thymocyte serum
[139].
An alternative possibility to explain why reducing renal TxA2
synthesis is protective against glomerulosclerosis emerged from
studies showing that PGH2ITxA2 analogs induce a dose-depen-
dent increase in laminin A, B1 and B2 chains in tumor cells in
culture and that these effects are reversed by a thromboxane
receptor antagonist [140]. This possibility is further supported
by the recent observation that a thromboxane synthase inhibi-
tor ameliorated progressive diabetic nephropathy and pre-
vented the increase in type IV collagen mRNA levels in mice
with non-insulin dependent diabetes mellitus [141].
Implications of pharmacologic studies
PGH2 and TxA2 exert multiple actions within the kidney
which may contribute to the progression of renal disease. These
include constriction of glomerular afferent and efferent arteri-
oles, intraglomerular platelet aggregation, contraction of gb-
merular mesangial cells and proliferation of mesangial cell
matrix. These effects have been characterized using stable
PGH2/TxA2 analogs and although radioligand studies suggest a
single class of specific binding sites in glomeruli, it is unclear
whether these are subtypes distinct from those in platelets and
vascular smooth muscle cells and whether their affinity for
PGH2 and TxA2 is similar. In this regard, much of the informa-
tion suggesting the functional importance of this system has
been obtained with specific inhibitors of thromboxane synthase,
an intervention that might be expected to lead to accumulation
of PGH2, coincidental with inhibition of TxA2 synthesis.
Such studies have implicated TxA2 in the nephrotoxicity of
pharmacologic, immune and toxic insults, in the progression of
chronic renal disease and in renal albograft rejection. Biochem-
ical assessment of renal biosynthesis of TxA2 has facilitated the
identification of potential targets for pharmacological interven-
tion. This evidence has been accumulated particularly in animal
models, but also, to a limited extent, in humans. It suggests that
pharmacological inhibition of TxA2 synthesis or action merits
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Table 2. Thromboxane A2 in experimental and human renal diseases
Changes in urinary
Site of abnormal excretion of Effect of pharmacological inhibition
Disease model TxA2 synthesis TxA2 metabolites of TxA2 synthase/receptor
Experimental
Endotoxin-induced ARF (rat) cortex [1181
Nephrotoxic nephritis (rat) glomeruli [74] proteinuria, f GFR and RPF [741
Glycerol-induced ARF (rat) glomeruli [79] '[ GFR [80]
Adriamycin nephrosis (rat) glomeruli [1021 1 TxB2 [102] . proteinuria [102]
Puromycin nephrosis (rat) proteinuria [103]
Passive Heymann nephritis proteinuria [105]
(rat)
STZ-induced diabetes (rat) TxB [107] . albuminuria, GFR [107]
Milan normotensive strain glomeruli [1191 proteinuria [1101
(rat)
Nephrotoxic nephritis (rabbit) glomeruli [112] 1 proteinuria, ' GFR [112]
CsA nephrotoxicity (rat) glomeruli [121]
'
TxB2 [119, 120, 121]
2,3-dinor-TxB [120, 121]
1 GFR [119]
Endotoxin-induced ARF (rat) cortex [122] 1' GFR and RPF [122]
Ureteral obstruction (rat, kidney microsomes 1' GFR and RBF [124]
rabbit) [123]
Renal allograft rejection (rat) 1 GFR and RPF [128]
Renal mass ablation (rat) TxB [131] 1 proteinuria, GFR and RPF, I FSG [131]
Dahl-S strain (rat) glomeruli [134] proteinuria, GFR, I FSG [134]
Noninsulin-dependent diabetes cortex type IV collagen mRNA [141]
(mouse)
Lupus nephritis (mouse) cortex [126, 127]
medulla [126]
1 GFR [1271
Clinical
Lupus nephritis TxB2 [88] 1 GFR and RPF [88]
Nephrotic syndrome I 2,3-dinor-TxB2 [106] 1 proteinuria [106]
CsA nephrotoxicity 2,3-dinor-TxB [118]
continued evaluation in the treatment of a variety of renal
diseases in humans.
Because PGH2 shares with TxA2 many of the renal actions
that have been discussed in this review, it is puzzling that
pharmacological blockade of thromboxane synthase, which
results in accumulation of PGH2 in platelets [142, 1431, was
shown so consistently effective in ameliorating TxA2—dependent
loss of renal function and structure. This is at variance with the
rather disappointing results obtained with thromboxane-syn-
thase inhibitors when used as potential antithrombotic agents
[1441. A number of studies both in vitro [1451 and in vivo [146,
147] have demonstrated that PG endoperoxides modulate the
functional response of platelets to thromboxane synthase inhi-
bition and may, in fact, substitute for the proaggregatory
activity of TxA2.
Several factors might contribute to this apparent discrep-
ancy. These include: (a) a different biosynthetic capacity of
platelets, vis-à-vis glomerular cells, in producing TxA2, result-
ing in different levels of "critical" pharmacological suppres-
sion; (b) a lower affinity of PGH2 than TxA2 for the putatively
shared glomerular mesangial and arteriolar receptor(s); (c) a
markedly different metabolic fate of PGH2 in platelets (largely
converted to TxA2 by thromboxane synthase) versus glomeru-
lar mesangial and epithelial cells (perhaps largely converted to
PGE2 and PGI2 by other isomerases) resulting in much greater
accumulation of PGH2 in platelets than in glomerular cells, in
the face of comparable blockade of thromboxane synthase.
Whether PGH2/TxA2-receptor antagonists may mimic or en-
hance the renal effects of thromboxane synthase inhibitors
largely remains to be investigated and may shed some light on
this controversial issue.
Summary and conclusions
PGH2 and TxA2 exert their actions via tissue specific, recep-
tor isoforms. PGH2/TxA2-dependent platelet aggregation and
contraction of vascular and bronchial smooth muscle and of
glomerular mesangial cells occur via receptors linked to activa-
tion of phospholipase C.
Although PGH2/TxA2 appear to be of little importance in the
maintenance of renal function under physiological circum-
stances, increased renal TxA2 biosynthesis has been docu-
mented in a variety of animal models of renal disease and in
some clinical disorders (Table 2). The effects of this eicosanoid
on renal tissues in vitro and of pharmacological manipulation of
TxA2 synthesis and action in vivo suggest that such interven-
tions will provide new drugs for the treatment of human kidney
disease.
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